Marathon Pharmaceuticals
 |
|
| Private | |
| Industry | Pharmaceuticals |
| Founder | Jeffrey S. Aronin |
| Headquarters | Northbrook, Illinois, USA |
|
Area served
|
Worldwide |
|
Key people
|
Jeffrey S. Aronin, Chairman and CEO |
| Products | Develops drugs for high-need, small patient populations, and late stage |
Marathon Pharmaceuticals LLC is a privately held biopharmaceuticals company focused on drugs for people with rare diseases. The Northbrook, Illinois-based company develops and manufactures therapeutics and brings them to market. It employs 100 people in four global locations.
Marathon produces medicines for high-need, small patient populations, including patients with rare diseases as outlined by the U.S. Food and Drug Administration’s (FDA) Orphan Drug Act. The Act defines rare diseases as impacting fewer than 200,000 patients in the U.S.
Marathon develops late-stage drugs, earns regulatory approvals, and then manufactures and commercializes medicines with input from patient advocacy groups. Marathon’s regulatory efforts center on gaining FDA approval of New Drug Applications (NDA) or Biologic License Applications (BLA).
The company provides assistance for eligible patients with financial hardship and helps patients secure other assistance through the National Organization of Rare Disorders (NORD) and similar patient support groups.
Marathon distributes its products in North America.
Marathon develops medications that target neurological, muscular, gastrointestinal and blood disorders, including deflazacort, a new medication to slow the progression of Duchenne Muscular Dystrophy (DMD) in patients. In January 2015, Marathon was granted fast track status from FDA for deflazacort as a potential treatment for DMD. Exondys 51 and deflazacort are, as of 2/12/2017, the only FDA-approved drugs that treat DMD. Most patients usually die by age 25, although recently some people have lived into their 30s and 40s with assistive devices and support.
...
Wikipedia